Skip to main content
. 2021 Jan 14;10:586414. doi: 10.3389/fonc.2020.586414

Figure 7.

Figure 7

Disease-specific survival (DSS) curves using combinations SLC41A3 expression and Immune cells score. (A) DSS analysis of combinations SLC41A3 expression and B cell score in liver hepatocellular carcinoma (LIHC). (B) DSS analysis of combinations SLC41A3 expression and CD4+ T cell score in LIHC. (C) DSS analysis of combinations SLC41A3 expression and Macrophage cell score in LIHC. (D) DSS analysis of combinations SLC41A3 expression and Neutrophil cell score in LIHC. (E) DSS analysis of combinations SLC41A3 expression and neutrophil cell score in sarcoma (SARC). (F) DSS analysis of combinations SLC41A3 expression and CD4+ T cell score in uveal melanoma (UVM). (G) DSS analysis of combinations SLC41A3 expression and CD8+ T cell score in UVM. (H) DSS analysis of combinations SLC41A3 expression and neutrophil cell score in UVM. p< 0.05 was considered significant.